Mechanisms of pharmacologic cardioversion of atrial fibrillation by Class I drugs. 1998

M A Allessie, and M C Wijffels, and R Dorland
Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands.

BACKGROUND We recently developed a goat model of sustained atrial fibrillation (AF) in which repetitive induction of AF by burst pacing shortened the atrial effective refractory period (AERP) (electrophysiologic remodeling) and progressively prolonged the paroxysms of AF to become sustained (24 hours) within 1 to 3 weeks (atrial fibrillation begets atrial fibrillation). The aim of the present study was to study the effect of Class I drugs in this animal model of chronic AF. RESULTS The effects of hydroquinidine (HQ) on seven chronically fibrillating goats and of flecainide (Fl) on nine goats were studied. Both drugs were infused intravenously until sustained AF was cardioverted or adverse drug effects occurred. HQ and Fl restored sinus rhythm in 86% and 67% of the cases. Adverse drug effects occurred in 14% and 56%, respectively. The average atrial cycle length of AF (AFCL) was prolonged to a different degree. Just before restoration of sinus rhythm, the two drugs had increased AFCL by 72% and 50%. The duration of the QRS complex was prolonged 17% by HQ and 50% by Fl. The RR interval was not affected by HQ and was prolonged slightly by Fl. Directly after restoration of sinus rhythm, the AERP during pacing with an interval of 400 msec was 92 +/- 29 (HQ) and 66 +/- 10 msec (Fl) (control value: 149 +/- 10 msec). Intra-atrial conduction velocity was 83 +/- 7 and 86 +/- 11 cm/sec (control value: 116 +/- 10 cm/sec). Although both drugs were effective in terminating AF, after cardioversion the atrial vulnerability was still very high and a single premature stimulus reinduced AF in 100% of the animals. As a result of the short AERP by the AF-induced remodeling and the depressed intra-atrial conduction by the Class I drugs, directly after cardioversion the atrial wavelength was abnormally short (between 5.7 and 7.5 cm). This explains the still high atrial vulnerability to AF directly after cardioversion by Class I drugs. Surprisingly, the prolongation of AFCL by either Class I drug was not due to lengthening of the functional refractory period but rather to a widening of the excitable gap during AF. CONCLUSIONS In a goat model of chronic AF, infusion of Class IA and Class IC drugs restored sinus rhythm in 67% to 86% of the cases. However, due to the short AERP and the depressed intra-atrial conduction directly after cardioversion, the atrial vulnerability was still very high and a premature beat easily reinduced AF.

UI MeSH Term Description Entries
D004554 Electric Countershock An electrical current applied to the HEART to terminate a CARDIAC ARRHYTHMIA. Cardiac Electroversion,Cardioversion,Defibrillation, Electric,Electroversion, Cardiac,Electrical Cardioversion,Electroversion Therapy,Therapy, Electroversion,Cardiac Electroversions,Cardioversion, Electrical,Cardioversions,Cardioversions, Electrical,Countershock, Electric,Countershocks, Electric,Defibrillations, Electric,Electric Countershocks,Electric Defibrillation,Electric Defibrillations,Electrical Cardioversions,Electroversion Therapies,Electroversions, Cardiac,Therapies, Electroversion
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001281 Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation. Auricular Fibrillation,Familial Atrial Fibrillation,Paroxysmal Atrial Fibrillation,Persistent Atrial Fibrillation,Atrial Fibrillation, Familial,Atrial Fibrillation, Paroxysmal,Atrial Fibrillation, Persistent,Atrial Fibrillations,Atrial Fibrillations, Familial,Atrial Fibrillations, Paroxysmal,Atrial Fibrillations, Persistent,Auricular Fibrillations,Familial Atrial Fibrillations,Fibrillation, Atrial,Fibrillation, Auricular,Fibrillation, Familial Atrial,Fibrillation, Paroxysmal Atrial,Fibrillation, Persistent Atrial,Fibrillations, Atrial,Fibrillations, Auricular,Fibrillations, Familial Atrial,Fibrillations, Paroxysmal Atrial,Fibrillations, Persistent Atrial,Paroxysmal Atrial Fibrillations,Persistent Atrial Fibrillations

Related Publications

M A Allessie, and M C Wijffels, and R Dorland
February 2009, Cardiology clinics,
M A Allessie, and M C Wijffels, and R Dorland
December 2005, American family physician,
M A Allessie, and M C Wijffels, and R Dorland
January 2008, The Medical clinics of North America,
M A Allessie, and M C Wijffels, and R Dorland
October 1994, Australian and New Zealand journal of medicine,
M A Allessie, and M C Wijffels, and R Dorland
May 1998, Journal of the American College of Cardiology,
M A Allessie, and M C Wijffels, and R Dorland
August 1998, Journal of cardiovascular electrophysiology,
M A Allessie, and M C Wijffels, and R Dorland
February 2021, The American journal of cardiology,
M A Allessie, and M C Wijffels, and R Dorland
December 1998, Giornale italiano di cardiologia,
M A Allessie, and M C Wijffels, and R Dorland
January 1999, Minerva cardioangiologica,
M A Allessie, and M C Wijffels, and R Dorland
June 2006, Journal of cardiovascular electrophysiology,
Copied contents to your clipboard!